NEW YORK – Oncimmune Holdings has signed a deal with Dana-Farber Cancer Institute to use its biomarker discovery engine SeroTag to identify autoantibodies that can characterize patients' responses to checkpoint inhibitors and chemotherapies the cancer center is studying in clinical trials.
Within the deal, Dana-Farber will use Oncimmune's high-throughput discovery array, SeroTag, which is part of its ImmunoInsights platform for biomarker discovery and validation. The institute will use SeroTag to identify cancer-linked antigens predictive of therapeutic response or resistance, as well as assess immune-related adverse events.
Researchers will also use the autoantibody profiling technology in Dana-Farber-led studies of biomarkers to guide therapeutic decisions for patients considering treatment with atezolizumab (Roche/Genentech's Tecentriq), nivolumab (Bristol Myers Squibb's Opdivo), pembrolizumab (Merck's Keytruda), durvalumab (AstraZeneca's Imfinzi), and cisplatin-based chemotherapy. The project is slated to complete by year-end.
"As autoantibodies continue to be recognized as a key biomarker class that aid in the understanding of interactions between cancer and the immune system, the ImmunoInsights platform is becoming increasingly instrumental in studies for a wide range of cancer indications and therapy classes," Oncimmune CEO Adam Hill said in a statement.
According to Nottingham, UK-based Oncimmune, its SeroTag technology can analyze autoantibodies from "just a few drops of serum," and is being used to discover and validate biomarkers and develop diagnostics. The company's autoantibody profiling tools are also being used to discover biomarkers of COVID-19.